Figure 4. SARS-CoV-2–Specific IgG+ Memory B-Cell Response Measured in Patients With MS on Treatment With Teriflunomide (A) and S1P Modulators (B), With Relative CD19+ B-Cell Counts at t0 (Before First Vaccine Dose) and Anti-S IgG Measured at t1 (21–35 Days After the Second Dose).

Numbers in the bottom panels indicate frequency of S-specific memory B cells in 10e⁶ peripheral blood mononuclear cells (PBMCs). Anti-S = antispike; MS = multiple sclerosis; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.